QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
NASDAQ:RVMD

Revolution Medicines (RVMD) Stock Forecast, Price & News

$27.00
+1.18 (+4.57%)
(As of 06/6/2023 ET)
Compare
Today's Range
$25.81
$27.08
50-Day Range
$20.28
$27.00
52-Week Range
$15.64
$31.37
Volume
942,700 shs
Average Volume
1.08 million shs
Market Capitalization
$2.87 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$33.00

Revolution Medicines MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.86 Rating Score
Upside/​Downside
22.2% Upside
$33.00 Price Target
Short Interest
Bearish
8.88% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.81
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Acquiring Shares
$14.15 M Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.47) to ($3.71) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.77 out of 5 stars

Medical Sector

745th out of 981 stocks

Biological Products, Except Diagnostic Industry

115th out of 156 stocks


RVMD stock logo

About Revolution Medicines (NASDAQ:RVMD) Stock

Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Receive RVMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Revolution Medicines and its competitors with MarketBeat's FREE daily newsletter.

RVMD Stock News Headlines

Revolution Medicines (NASDAQ:RVMD) Shares Down 5%
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
Revolution Medicines (NASDAQ:RVMD) PT Lowered to $35.00
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
The Latest Analyst Ratings for Revolution Medicines
Q1 2023 Revolution Medicines Inc Earnings Call
Revolution Medicines: Advancing On Several Fronts
Revolution Medicines (NASDAQ:RVMD) Trading 7.6% Higher
See More Headlines

RVMD Price History

RVMD Company Calendar

Last Earnings
5/08/2023
Today
6/06/2023
Next Earnings (Estimated)
8/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RVMD
Fax
N/A
Employees
188
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$33.00
High Stock Price Forecast
$38.00
Low Stock Price Forecast
$23.00
Forecasted Upside/Downside
+22.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
7 Analysts

Profitability

Net Income
$-248,710,000.00
Net Margins
-744.36%
Pretax Margin
-745.57%

Debt

Sales & Book Value

Annual Sales
$35.38 million
Book Value
$7.72 per share

Miscellaneous

Free Float
97,276,000
Market Cap
$2.87 billion
Optionable
Not Optionable
Beta
1.44

Key Executives

  • Dr. Mark A. Goldsmith Ph.D. (Age 61)
    CEO, Pres & Chairman
    Comp: $1.01M
  • Mr. Jack AndersMr. Jack Anders (Age 46)
    Chief Financial Officer
    Comp: $462.13k
  • Ms. Margaret A. Horn J.D. (Age 60)
    Chief Operating Officer
    Comp: $773.03k
  • Dr. Stephen M. Kelsey FRC Path. (Age 62)
    FRCP, M.D., Pres of R&D
    Comp: $773.03k
  • Ms. Xiaolin WangMs. Xiaolin Wang (Age 52)
    Exec. VP of Clinical Devel.
    Comp: $582.43k
  • Dr. Martin D. Burke M.D.
    Ph.D., Co-Founder & Chairman of Scientific Advisory Board
  • Dr. Michael A. Fischbach Ph.D. (Age 42)
    Academic Co-Founder & Member of Scientific Advisory Board
  • Dr. Kevan M. Shokat Ph.D.
    Academic Co-Founder & Member of Scientific Advisory Board
  • Mr. David L. Pompliano Ph.D.
    Founding Chief Scientific Officer
  • Mr. Walter Reiher Ph.D.
    Chief Information Officer













RVMD Stock - Frequently Asked Questions

Should I buy or sell Revolution Medicines stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Revolution Medicines in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RVMD shares.
View RVMD analyst ratings
or view top-rated stocks.

What is Revolution Medicines' stock price forecast for 2023?

7 equities research analysts have issued 12 month price targets for Revolution Medicines' stock. Their RVMD share price forecasts range from $23.00 to $38.00. On average, they anticipate the company's stock price to reach $33.00 in the next year. This suggests a possible upside of 22.2% from the stock's current price.
View analysts price targets for RVMD
or view top-rated stocks among Wall Street analysts.

How have RVMD shares performed in 2023?

Revolution Medicines' stock was trading at $23.82 at the beginning of the year. Since then, RVMD stock has increased by 13.4% and is now trading at $27.00.
View the best growth stocks for 2023 here
.

When is Revolution Medicines' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our RVMD earnings forecast
.

How were Revolution Medicines' earnings last quarter?

Revolution Medicines, Inc. (NASDAQ:RVMD) posted its earnings results on Monday, May, 8th. The company reported ($0.72) EPS for the quarter, beating analysts' consensus estimates of ($0.84) by $0.12. The company had revenue of $7.01 million for the quarter, compared to the consensus estimate of $2.94 million. Revolution Medicines had a negative trailing twelve-month return on equity of 36.79% and a negative net margin of 744.36%. The firm's quarterly revenue was down 7.4% compared to the same quarter last year. During the same period last year, the business posted ($0.78) EPS.

What other stocks do shareholders of Revolution Medicines own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Revolution Medicines investors own include Alector (ALEC), Editas Medicine (EDIT), Homology Medicines (FIXX), Gossamer Bio (GOSS), Livongo Health (LVGO), Sorrento Therapeutics (SRNE), Black Diamond Therapeutics (BDTX), Beam Therapeutics (BEAM), CrowdStrike (CRWD) and Precision BioSciences (DTIL).

When did Revolution Medicines IPO?

(RVMD) raised $150 million in an IPO on Thursday, February 13th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen, SVB Leerink and Guggenheim Securities served as the underwriters for the IPO.

What is Revolution Medicines' stock symbol?

Revolution Medicines trades on the NASDAQ under the ticker symbol "RVMD."

Who are Revolution Medicines' major shareholders?

Revolution Medicines' stock is owned by a number of institutional and retail investors. Top institutional investors include Wellington Management Group LLP (9.81%), BlackRock Inc. (7.02%), EcoR1 Capital LLC (5.03%), Price T Rowe Associates Inc. MD (4.74%), BVF Inc. IL (4.66%) and Nextech Invest Ltd. (4.55%). Insiders that own company stock include Anthony W Boor, Barbara Weber, Elizabeth M Anderson, Jack Anders, Jeanna Steele, Lorence H Kim, Margaret A Horn, Mark A Goldsmith, Peter Svennilson, Rock Ventures Ii LP Third, Rock Ventures Iii LP Third, Stephen Michael Kelsey, Thilo Schroeder, Vincent A Miller and Xiaolin Wang.
View institutional ownership trends
.

How do I buy shares of Revolution Medicines?

Shares of RVMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Revolution Medicines' stock price today?

One share of RVMD stock can currently be purchased for approximately $27.00.

How much money does Revolution Medicines make?

Revolution Medicines (NASDAQ:RVMD) has a market capitalization of $2.87 billion and generates $35.38 million in revenue each year. The company earns $-248,710,000.00 in net income (profit) each year or ($3.04) on an earnings per share basis.

How many employees does Revolution Medicines have?

The company employs 188 workers across the globe.

How can I contact Revolution Medicines?

Revolution Medicines' mailing address is 700 Saginaw Drive, Redwood City CA, 94063. The official website for the company is www.revmed.com. The company can be reached via phone at 650-481-6801 or via email at ir@revmed.com.

This page (NASDAQ:RVMD) was last updated on 6/6/2023 by MarketBeat.com Staff

My Account -